AI SEO for Pharma and Biotech
Pharma and biotech companies get recommended by ChatGPT and Google AI Overviews when AI can verify who they are, what they make and the evidence behind it. Publish plain pages on each capability, name your sites and regulatory status, link to public inspection and registry records, and support claims with papers. Nobody can promise placement, and answers change between runs.
- Buyers in B2B use AI heavily: 45% of buyers in one Gartner survey used GenAI during a recent purchase. 1
- In one 6sense study, 95% of buyers picked a vendor from their Day One shortlist, so being named early matters. 2
- Public FDA and EU inspection records exist for manufacturers, so claims can be checked. 46
- Google sets a higher accuracy bar for health topics, so we suggest a named reviewer and a source for every claim. 9
- Chalk Labs has no published pharma or biotech results. We have used the method on a trophy shop and a personal site. 12
How do pharma and biotech buyers use AI to find suppliers?
They use it to build and test a shortlist, but no study we could find measures this for CDMO or biotech buyers. The best evidence comes from B2B buying in general, so treat it as a guide and not as pharma data.
Gartner surveyed 645 B2B buyers in 2025: 45% used GenAI during a recent purchase, mainly to gather vendor information, and 69% prefer to check AI insights with a sales rep 1. In 6sense's 2025 study of nearly 4,000 buyers, 94% used large language models, mostly to compare vendors, and 95% chose from their Day One shortlist 2.
For a company selling biologics manufacturing, this means two things. AI may help build the first list, and a human will then check it against inspection records, papers and a call with your team. Your public pages must survive that second check.
What do AI engines look at when they pick a biologics supplier?
They look for pages that state facts plainly and can be matched to other sources. Google says a page must be indexed and eligible to show with a snippet to be a supporting link in AI Overviews and AI Mode, with no extra technical requirements 10. No special markup or AI text file is needed.
Google holds health, safety and finance content to a higher accuracy bar 9. A B2B supplier page is not clearly in that group, but it describes products that affect patients, so we suggest treating it as if it is.
Google's guidance asks three questions: who made the content, how it was made, and why. Name the scientists and quality leads behind each page, and link each name to a profile with real credentials 9. Google warns against made-up names or false credentials that make content look as if human experts wrote it 9. Use real people with checkable credentials.
- Site facts: location, scale range, modalities such as mammalian cell culture or microbial fermentation, and what you do not do.
- Regulatory facts: which regulators have inspected which site, with links to the public record where one exists.
- People: named heads of quality, manufacturing and science, with verifiable backgrounds.
- Publications: papers, posters and white papers that other sources cite.
Why do inspection records and papers matter more than blog posts?
Because buyers and AI can check them, and they are hard to fake. FDA says it monitors manufacturers' compliance with current good manufacturing practice (CGMP), the minimum requirements for methods, facilities and controls 3. The page lists 21 CFR Parts 210 and 211 for finished pharmaceuticals and Part 600 for biological products 3.
FDA publishes final inspection classifications in a public database, using three labels: No Action Indicated, Voluntary Action Indicated and Official Action Indicated 4. FDA says the database is not a complete list of inspections, and it leaves out some types such as pre-approval inspections 4. FDA also posts warning letters in a public, searchable list 5.
In the European Union, the EudraGMDP database lets the public search GMP certificates and non-compliance reports. Its content comes from national authorities, and EMA says it accepts no responsibility for the information 6.
Do not paste these records into your pages as marketing. Link to the live record, state the date you last checked it, and say plainly what a classification means. A supplier that makes its own audit trail easy to verify gives a buyer and an AI engine something firm to repeat.
| Record | What it shows | What to publish |
|---|---|---|
| FDA inspection classification database | Final classification per inspection project area, with exclusions 4 | A link to the record for each site and the date you checked it |
| FDA warning letters list | Public, searchable letters, whose status may have changed later 5 | A short statement that none are open, if true, and a link to the list |
| EudraGMDP | GMP certificates and non-compliance reports for EU sites 6 | Certificate numbers and the link, for each EU site |
What do buyers ask AI, and what should you publish for each question?
Buyers ask comparison and fit questions first, then narrow to capacity and risk. The first prompt below is the one this page tracks. The rest are modelled prompts we expect, not observed ones, so test them on your own accounts.
Each prompt maps to a page you can publish. A page that answers the question directly, with named sites and checkable facts, is easier for an AI engine to quote than a brochure.
| Prompt | What the buyer needs | Page to publish |
|---|---|---|
| who are the leading CDMOs for biologics manufacturing | A shortlist with reasons | An honest capabilities overview with sites, modalities and scale ranges |
| CDMO for monoclonal antibody manufacturing at 2,000 L scale | A capacity match | A single-use bioreactor scale page with batch sizes and lead times you can state |
| how long does tech transfer to a CDMO take | A realistic timeline | A tech transfer guide with phases, inputs and what slows it down |
| what should I ask a CDMO before signing a contract | A due-diligence checklist | A buyer's checklist that includes your inspection history |
| CDMO in Europe with a recent EU GMP certificate | A regional fit | A site page with certificate numbers and the EudraGMDP link |
What should a biotech or CDMO publish first?
Publish the capabilities overview first, then one page per site and per modality. These pages answer the seed prompt and the narrower ones that follow from it. Write each in plain language, with the technical detail below the first paragraph.
Next, publish a tech transfer guide and a buyer's checklist. These are the pages a procurement lead copies into a document. Then add a science library with short summaries that link to the original papers, written or reviewed by a named scientist.
Skip thin pages. Google warns against making content mainly to attract search visits, and says the reason a page exists matters most 9. A page that exists to help a buyer decide is fine. A page made to repeat a keyword is not.
- [Company] manufactures monoclonal antibodies and recombinant proteins from [city, country] and [city, country].
- Scale range: [X] L to [Y] L single-use bioreactors. Typical tech transfer: [N] months, depending on process maturity.
- Regulatory record: last FDA inspection [month, year], classification [as shown in the public database], link [url].
- We do not offer: [list what you do not do, such as cell therapy or fill-finish].
What rules and limits apply to pharma and biotech content?
The rules depend on what you sell and where. This is general information, not legal or regulatory advice, so have your regulatory affairs team review every page.
FDA's Office of Prescription Drug Promotion works to keep prescription drug promotion truthful, balanced and accurately communicated, and it issues compliance letters for false or misleading materials 7. If your pages promote a marketed drug, those rules matter. A contract manufacturer that describes capabilities and does not promote a client's product faces a different question, but check with counsel before you describe any client programme.
Never name a client, programme or molecule without written permission, because confidentiality clauses are common in this field. Do not state or imply efficacy, safety or approval status for any product unless you can cite the label or approval record. State what you cannot show, such as pending inspections, as pending.
How do you measure whether AI is bringing supplier enquiries?
Track named share in AI answers, enquiry source and qualified conversations. Run a fixed list of 8 to 10 prompts each month on two AI engines, three runs each, and log which suppliers appear. Answers vary by run, so one result tells you little.
Web analytics will undercount. Pew found that in March 2025 users clicked a traditional result link in 8% of visits with a Google AI summary, against 15% without one 11. A reader may see your name in an answer and never click. Ask every enquiry how they first heard of you, and record 'AI assistant' as an option.
In Search Console, traffic from AI Overviews and AI Mode is counted in the Web search type 10. Compare each month with the same month last year, because sales cycles in this field are long. See How to Build a Prompt List for AI Visibility Tracking and How to Set Up Self-Reported Attribution for AI Leads.
What have Chalk Labs and Rahil Jain done in this field, and what have they not?
We have not published results in pharma or biotech. Chalk Labs ran its method (query research, answer pages, technical readiness, measurement) for Meru Trophy, a trophy shop in Bengaluru, and reports 27,300 Google clicks and 2.3M impressions over 16 months, taken from the client's Search Console 12.
It also built shilikajain.com, a personal-brand site that Chalk Labs reports ranked first for one niche phrase within a month of launch 12. Both are very different from a regulated science business, and the figures are Google search numbers, not AI citation counts.
Rahil Jain runs Chalk Labs' AI SEO programme, and Chalk Labs sells AI SEO services, so we have a commercial interest here. A regulatory team that knows your evidence is better placed to write the science itself. Our relevant part is the structure and measurement. See also AI SEO for Medical Devices and AI SEO for B2B SaaS for other long-cycle fields.
Your first 90 days
Days 1-30
- Run the 5 buyer prompts on two AI engines, three runs each, and save the answers.
- Audit every regulatory statement on the site against the live public record.
- Add named authors and reviewers to existing science pages.
- Check that key pages are indexed and readable without scripts.
Days 31-60
- Publish the capabilities overview and one page for each site.
- Publish a regulatory record page that links to the public databases.
- Publish a tech transfer guide reviewed by your head of quality.
Days 61-90
- Publish a buyer's checklist and a modality page for your main platform.
- Add 'How did you hear about us?' with an AI option to the contact form.
- Rerun the prompt log, compare with day one and plan the next quarter.
The first pages to publish
- Capabilities overview. It answers the seed prompt and gives AI a quotable summary of sites, modalities and scale.
- One page per manufacturing site. Buyers ask by location and regulator, so each site needs its own facts.
- Regulatory record. It links to public inspection and certificate records that a buyer can verify.
- Tech transfer guide. It answers a high-intent timeline question with phases and inputs.
- How to choose a CDMO. A neutral checklist earns trust and is easy to quote.
- Science library with paper links. It connects your claims to the papers that other sources cite.
- Quality system overview. It explains change control, deviations and audits in plain terms.
- Team and credentials. Named people with real backgrounds support trust.
Trust signals and risks
What AI looks for
Why Rahil Jain for Pharma and Biotech?
Method applies
We have not published results of our own in Pharma and Biotech yet. What transfers is the method, shown below.
We have not published results in this field yet. Our method has only been used on a local shop and a personal site. A regulated science business needs its own qualified reviewers for the content itself.
Rahil Jain
Rahil Jain is an AI SEO (answer engine and generative engine optimisation) consultant and co-founder of Chalk Labs.
Results we can show
These are Chalk Labs' own search results. They are not a forecast for your site: results depend on your market, competition and starting point.
How to read these numbers
Chalk Labs reports them from Google Search Console data. We cannot publish the raw console. The shilikajain.com site belongs to Shilika Jain, a Chalk Labs co-founder, so treat it as a demonstration on our own network and not as an independent client result. Meru Trophy is a client of Chalk Labs.
Frequently asked questions
Can a CDMO or biotech company really get recommended by ChatGPT?
It can be named, but nobody can promise it. We found no published study that measures how often ChatGPT names a CDMO. B2B buyers do use AI: 45% used GenAI in a recent purchase in one Gartner survey 1. We do not guarantee placement in any AI answer.
Do I need schema markup or an llms.txt file?
Not to appear in Google's AI features. Google says a page must be indexed and eligible to show with a snippet, with no additional technical requirements and no special AI files 10. Markup is still useful if it matches the visible text, but it is not a switch that turns on citations.
Can I publish my FDA inspection result on my website?
Public FDA classifications are public, but state them accurately. FDA says its inspection database is not a complete list and excludes some inspection types 4. Link to the live record, give the date you checked it, and have regulatory counsel review the wording. This is not legal advice.
Can I name clients or programmes in case studies?
Only with written permission. Confidentiality terms are common in contract manufacturing, and naming a client can breach them. Describe the type of work, such as a monoclonal antibody at clinical scale, and publish detail only where the client has agreed in writing.
How long until AI search brings supplier enquiries?
No one can say for this field. Chalk Labs' published search cases (Meru Trophy and a personal site) give results over months, and neither is a regulated science business 12. Sales cycles for manufacturing partners are long, so measure over quarters and compare with the same quarter last year.
Sources
- Gartner Survey Finds 69% of B2B Buyers Turn to Sales Reps to Validate AI-Generated Insights · GartnerOpened October 20, 2026. Supports: Survey of 645 B2B buyers (August to September 2025, published 20 May 2026): 45% used GenAI during a recent purchase, mainly for vendor and product information; 69% prefer to validate AI insights with sales reps; an average of seven information sources. Cross-industry, not pharma-specific.
- 2025 B2B Buyer Experience Report · 6senseOpened October 20, 2026. Supports: Study of nearly 4,000 B2B buyers (2025): 94% use LLMs in buying; comparing vendor offerings is the top use; 95% of buyers chose from the Day One shortlist, up from 85%. Cross-industry, not pharma-specific.
- Current Good Manufacturing Practice (CGMP) Regulations · US Food and Drug AdministrationOpened October 20, 2026. Supports: FDA monitors manufacturers' CGMP compliance, minimum requirements for methods, facilities and controls; the page lists 21 CFR Parts 210 and 211 for finished pharmaceuticals and Part 600 for biological products.
- Inspection Classification Database · US Food and Drug AdministrationOpened October 20, 2026. Supports: Final classifications NAI, VAI and OAI per project area; not a complete list of inspections, and it excludes State-conducted, pre-approval and some other inspections; an Inspections Data Dashboard is updated weekly.
- Warning Letters · US Food and Drug AdministrationOpened October 20, 2026. Supports: FDA posts warning letters in a public, searchable list, and the regulatory status of issues in a letter may have changed after later FDA contact.
- EudraGMDP: GMP certificates and non-compliance search · European Medicines AgencyOpened October 20, 2026. Supports: Public database operated by EMA with content from national competent authorities; searchable GMP certificates and non-compliance reports; EMA accepts no responsibility for the information.
- Office of Prescription Drug Promotion (OPDP) · US Food and Drug AdministrationOpened October 20, 2026. Supports: OPDP works to ensure prescription drug promotion is truthful, balanced and accurately communicated, and issues compliance letters for false or misleading materials.
- About PubMed · National Center for Biotechnology Information, US National Library of MedicineOpened October 20, 2026. Supports: PubMed indexes biomedical literature citations and abstracts and does not host full-text articles.
- Creating helpful, reliable, people-first content · Google Search CentralOpened October 20, 2026. Supports: E-E-A-T and trust; stronger weight on E-E-A-T for topics affecting health, finances, safety or well-being; accuracy bar and expert consensus for YMYL; Who, How and Why; made-up names or false credentials are warned against as deceptive.
- AI features and your website · Google Search CentralOpened October 20, 2026. Supports: A page must be indexed and eligible to show with a snippet to be a supporting link in AI Overviews and AI Mode; no additional technical requirements; no special markup or AI files; AI feature traffic is included in Search Console's Web search type.
- Google users are less likely to click on links when an AI summary appears in the results · Pew Research CenterOpened October 20, 2026. Supports: March 2025 browsing data from 900 US adults: users clicked a traditional result link in 8% of visits with an AI summary and 15% without one.
- Chalk Labs case studies (Meru Trophy and shilikajain.com) · Chalk Labs (self-published)Opened October 20, 2026. Supports: Chalk Labs' own account: Meru Trophy reached 27,300 Google clicks and 2.3M impressions over 16 months, per the client's Google Search Console; shilikajain.com is reported to have ranked first for one niche phrase within a month of launch.